Search Results - "Jensen, Bradford K."

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure by Paccaly, Anne, Frick, Annke, Rohatagi, Shashank, Liu, Jingli, Shukla, Umesh, Rosenburg, Ronald, Hinder, Markus, Jensen, Bradford K.

“…The pharmacokinetics of otamixaban was investigated in healthy male subjects over a wide range of intravenous doses, with duration of administration varying…”
Get full text

Pharmacokinetics and Concentration-Effect Analysis of Intravenous RGD891, a Platelet GPIIb/IIIa Antagonist, Using Mixed-Effects Modeling (NONMEM) by Zannikos, Peter N., Rohatagi, Shashank, Jensen, Bradford K., DePhillips, Susan L., Rhodes, Gerald R.

“…RGD891 is a platelet GPIIb/IIIa receptor antagonist and potent inhibitor of platelet aggregation. This compound is biotransformed in vivo to RGD039, which also…”
Get full text

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects by Paccaly, Anne, Frick, Annke, Ozoux, Marie-Laure, Chu, Valeria, Rosenburg, Ronald, Hinder, Markus, Shukla, Umesh, Jensen, Bradford K.

“…Direct pharmacokinetic/pharmacodynamic relationships for otamixaban were investigated after rising doses in healthy subjects using mixed‐effect modeling…”
Get full text

Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects by Shah, Bharti, Rohatagi, Shashank, Natarajan, Chandrasekhar, Kirkesseli, Stephane, Baybutt, Robert, Jensen, Bradford K

“…RPR749 and its methylated metabolite are orally active and selective adenosine A(1) agonists that can inhibit lipolysis and lower plasma triglyceride levels in…”
Get full text

The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride by Krishna, Rajesh, Krishnaswami, Sriram, Kittner, Barbara, Sankoh, Abdul J., Jensen, Bradford K.

“…Fexofenadine hydrochloride is a non‐sedating antihistamine that is used in the treatment of symptoms associated with seasonal allergic rhinitis and chronic…”
Get full text

Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA-4 Antagonist, HMR1031 by Shah, Bharti, Jensen, Bradford K., Zhang, Jie, Hunt, Thomas, Rohatagi, Shashank

“…HMR1031 is a potent and specific antagonist of the integrin VLA‐4 (α4β1) binding to vascular cell adhesion molecule‐1 (VCAM‐1) and fibronectin. HMR1031 is an…”
Get full text

Estimating Mass Balance for Inhaled Drugs in Humans: An Example with a VLA-4 Antagonist, IVL745 by Rohatagi, Shashank, Shah, Bharti, Zhang, Jie, Zeng, Zhaopie, Kirkesseli, Stephane, Jensen, Bradford K.

“…IVL745 is an inhaled VLA‐4 antagonist developed for the treatment of asthma. Following inhalation (Inh), a fraction of the drug is deposited in the oropharynx,…”
Get full text

Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler by Rohatagi, Shashank, Chapel, Sunny, Kirkesseli, Stephane, Newman, Stephen, Zhang, Jie, Paccaly, Dominique, Randall, Linda, Wray, H, Wellington, Sheree, Shah, Bharti, Jensen, Bradford K

“…A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031 from the existing nebulizer formulation and the new Ultrahaler device to…”
Get full text

Pharmacokinetics of M100240 and MDL 100,173, a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, in Healthy Young and Elderly Volunteers by Emmons, Gary T., Argenti, Rick, Martin, Louis L., Martin, Nancy E., Jensen, Bradford K.

“…M100240 is an acetate thioester of MDL 100,173—a dual angiotensin‐converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitor—in phase II development. The…”
Get full text

Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects by Shah, Bharti, Emmons, Gary, Rohatagi, Shashank, Martin, Nancy E, Jensen, Bradford K

“…[4S-[4alpha,7alpha(R*),12bbeta]]-7[[2-(acetylthio)-1-oxo-3-phenylpropyl]amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo-pyrido[2,1-a][2]benzazepine-4-carboxylic acid…”
Get full text

Pharmacokinetic-Pharmacodynamic Modeling of the Antilipolytic Effects of an Adenosine Receptor Agonist in Healthy Volunteers by Zannikos, Peter N., Rohatagi, Shashank, Jensen, Bradford K.

“…ARA is an adenosine receptor agonist with high affinity for A1 and A2 receptors, which are involved in regulation of free fatty acid (FFA) production. Two…”
Get full text

A Mass Balance Study to Evaluate the Biotransformation and Excretion of [14C]-Triamcinolone Acetonide following Oral Administration by Argenti, Domenick, Jensen, Bradford K., Hensel, Russell, Bordeaux, Kirk, Schleimer, Robert, Bickel, Carol, Heald, Donald

“…The principle objective of this study was to characterize the absorption, metabolism, and disposition of orally administered [14C]‐triamcinolone acetonide. Six…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, following Intravenous Administration in Healthy Male Volunteers by Zannikos, Peter N., Rohatagi, Shashank, Jensen, Bradford K., DePhillips, Susan L., Massignon, Denis, Calic, Francoise, Sibille, Michel, Kirkesseli, Stephane

“…The pharmacokinetics (PK), pharmacodynamics (PD), and safety of a platelet GPIIb/IIIa receptor antagonist, RGD891, and its active metabolite, RGD039, were…”
Get full text

Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers by Zannikos, Peter N., Baybutt, Robert I., Boutouyrie, Bruno X., Shah, Bharti, Hunt, Thomas L., Jensen, Bradford K.

“…The pharmacokinetics of an adenosine agonist, AMP 579, following intravenous administration were evaluated. Single AMP 579 doses of 20 to 150 μg/kg were…”
Get full text

Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency by Zannikos, Peter N., Jensen, Bradford K., Boutouyrie, Bruno X., Tripp, Lisa, Yongyi, Luo, McGowan, Tracy, Waldman, Scott A., Greenberg, Howard E.

“…The pharmacokinetics of an adenosine agonist (AMP 579) were characterized in patients with end‐stage renal disease compared to sex‐ and age‐matched healthy…”
Get full text

Population pharmacokinetics/pharmacodynamics of ciclesonide by Rohatagi, Shashank, Arya, Vikram, Zech, Karl, Barrett, Jeff S, Hochhaus, Guenther, Jensen, Bradford K

Get full text

First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials by Giugliano, Robert P., McCabe, Carolyn H., Sequeira, Rafael F., Frey, Martin J., Henry, Timothy D., Piana, Robert N., Tamby, Jean-Francois, Jensen, Bradford K., Nicolas, Sylvain B., Jennings, Lisa K., Wise, Robert J., Braunwald, Eugene

“…Background RPR 109891 is a modified tetrapeptide glycoprotein IIb/IIIa inhibitor available in intravenous and oral formulations. Two phase II dose-ranging…”
Get full text

Pharmacokinetics, Safety, and Tolerability of Single Intravenous Infusions of an Adenosine Agonist, AMP 579, in Healthy Male Volunteers by Zannikos, Peter N, Baybutt, Robert I, Boutouyrie, Bruno X, Shah, Bharti, Hunt, Thomas L, Jensen, Bradford K

“…The pharmacokinetics of an adenosine agonist, AMP 579, following intravenous administration were evaluated. Single AMP 579 doses of 20 to 150 mu g/kg were…”
Get full text

Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency by Zannikos, Peter N, Jensen, Bradford K, Boutouyrie, Bruno X, Tripp, Lisa, Yongyi, Luo, McGowan, Tracy, Waldman, Scott A, Greenberg, Howard E

“…The pharmacokinetics of an adenosine agonist (AMP 579) were characterized in patients with end-stage renal disease compared to sex-and age-matched healthy…”
Get full text

Negligible Systemic Absorption of Topical Isotretinoin Cream: Implications for Teratogenicity by Chen, Chao, Jensen, Bradford K., Mistry, Goutam, Wyss, Ronald, Zultak, Maurice, Patel, Indravadan H., Rakhit, Ashok K.

“…The objective of the study was to assess the extent of systemic exposure of retinoic acid metabolites after excessive application of 0.1% isotretinoin cream in…”
Get full text